Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print March 13, 2003, 10.1148/radiol.2272020195
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2272020195v1
227/2/353    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bar-Shalom, R.
Right arrow Articles by Israel, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bar-Shalom, R.
Right arrow Articles by Israel, O.
(Radiology 2003;227:353-360.)
© RSNA, 2003

Nuclear Medicine

Camera-based FDG PET and 67Ga SPECT in Evaluation of Lymphoma: Comparative Study1

Rachel Bar-Shalom, MD, Nikolai Yefremov, MD, Nissim Haim, MD, Eldad J. Dann, MD, Ron Epelbaum, MD, Zohar Keidar, MD, Diana Gaitini, MD, Alex Frenkel, DSc and Ora Israel, MD

1 From the Departments of Nuclear Medicine (R.B.S., N.Y., Z.K., A.F., O.I.), Oncology (N.H., R.E.), Hematology (E.J.D.), and Diagnostic Radiology (D.G.), Rambam Medical Center and the Technion, Israel Institute of Technology, Bat Galim, Haifa 35254, Israel. Supported in part by a grant from the L. Rosenblatt Fund in Cancer Research of the Technion Foundation. Received March 4, 2002; revision requested May 22; final revision received August 29; accepted September 30. Address correspondence to O.I. (e-mail: o_israel@rambam.health.gov.il).

PURPOSE: To compare gallium 67 (67Ga) scintigraphy and camera-based fluorodeoxyglucose (FDG) positron emission tomography (PET) in the evaluation of patients with lymphoma.

MATERIALS AND METHODS: The performance of 67Ga scintigraphy and camera-based FDG PET in the detection of lymphoma was retrospectively evaluated and compared in 84 patients with lymphoma, with 219 suspected sites of disease. Eighty-nine percent of patients were examined during or after treatment. Camera-based FDG PET was initiated by equivocal characterization of the status of disease based on clinical, radiologic, and 67Ga scintigraphic assessment. Findings of 67Ga scintigraphy and camera-based FDG PET were compared on a per-patient and per-site basis for the whole group, for histologic subtypes, and for anatomic locations. Comparison of sensitivity, specificity, and accuracy between the two modalities for detection of lymphoma was performed with the McNemar test.

RESULTS: There was a statistically significant difference in sensitivity, specificity, and accuracy of 67Ga scintigraphy and camera-based FDG PET at both patient- and site-based analysis. 67Ga scintigraphy helped to accurately define disease state in 63% of patients and in 33% of sites, compared with 83% and 87%, respectively, for camera-based FDG PET. For discordant findings between the two modalities, camera-based FDG PET findings were confirmed as true-positive in 71% and as true-negative in 92% of patients. Camera-based FDG PET had a significantly higher detection rate for both nodal and extranodal lymphoma sites. It provided accurate assessment of lymphoma involvement of the skeleton in 93% of sites compared with 29% for 67Ga scintigraphy and excluded active lymphoma in 10 67Ga-positive benign parahilar sites.

CONCLUSION: In this selected group of patients with lymphoma, camera-based FDG PET allowed a significantly more accurate definition of active disease compared with that allowed with 67Ga scintigraphy.

© RSNA, 2003

Index terms: Fluorine, radioactive, 99.12963 • Gallium, radioactive, 99.12962 • Lymphoma, 99.8342, 99.8343 • Lymphoma, PET, 12963 • Lymphoma, SPECT, 99.12962 • Radionuclide imaging, comparative studies, 99.12962, 99.12963




This article has been cited by other articles:


Home page
 J Ultrasound MedHome page
M. Soudack, R. B. Shalom, O. Israel, Y. Ben-Arie, Z. Levy, and D. Gaitini
Utility of Sonographically Guided Biopsy in Metabolically Suspected Recurrent Lymphoma
J. Ultrasound Med., February 1, 2008; 27(2): 225 - 231.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
T. M. Blodgett, C. C. Meltzer, and D. W. Townsend
PET/CT: Form and Function
Radiology, February 1, 2007; 242(2): 360 - 385.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. J. Dann, R. Bar-Shalom, A. Tamir, N. Haim, M. Ben-Shachar, I. Avivi, T. Zuckerman, M. Kirschbaum, O. Goor, D. Libster, et al.
Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome
Blood, February 1, 2007; 109(3): 905 - 909.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
Y. Nishiyama, Y. Yamamoto, K. Fukunaga, H. Takinami, Y. Iwado, K. Satoh, and M. Ohkawa
Comparative Evaluation of 18F-FDG PET and 67Ga Scintigraphy in Patients with Sarcoidosis
J. Nucl. Med., October 1, 2006; 47(10): 1571 - 1576.
[Abstract] [Full Text] [PDF]